Compare Live Nation Entertainment, Inc. (LYV) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Natera Inc. Common Stock — how do they compare? Live Nation Entertainment, Inc. trades at $169.98 (market cap $39.91B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Live Nation Entertainment, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and Natera Inc. Common Stock for 0 Days on average.
| LYV | NTRA | |
|---|---|---|
Market Cap | $39.91B | $57.03B |
Volume | 1,800,962 | 1,131,157 |
Sector | Media | Health |
52-Week High | $188.46 | $425.64 |
52-Week Low | $125.61 | $179.42 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $42.12B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Live Nation Entertainment (LYV) trades at $168.84, down 0.47% on the day, with a neutral technical signal. The stock shows strong analyst support with an 86.96% buy rating and a $208.64 consensus price target, implying significant upside. Recent Q2 2026 earnings beat expectations with EPS of $1.05 versus $0.66 expected, driven by robust fan attendance and record deferred revenue. However, valuation metrics remain elevated with a P/E of 117.49 and P/B of 484.76, while profitability is thin with a net income margin of 0.51%.
The outlook is cautiously optimistic given strong demand for live events and strategic expansions, but high debt levels, regulatory scrutiny, and execution risks pose challenges. Revenue growth is projected to reach $26.3 billion in 2026, though net profit margins are expected to compress to 0.51%. Investors should weigh the bullish analyst sentiment against the stock's rich valuation and operational headwinds.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
